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Protocol
AbstrACt
Introduction Systemic treatment with alitretinoin 
is registered for all clinical types of severe chronic 
hand eczema. However, it is especially effective in 
the hyperkeratotic subtype and less effective in non-
hyperkeratotic forms. Cyclosporine A (cyclosporine) is 
prescribed for hand eczema in daily practice as well. 
It has shown to be particularly effective in patients 
with vesicular hand eczema. The primary objective 
of this study is to compare efficacy of alitretinoin and 
cyclosporine in the treatment of severe recurrent vesicular 
hand eczema.
Methods and analysis This is an investigator-initiated 
randomised prospective open-label trial with blinded 
outcome assessment. Severity assessments and 
laboratory measurements will be conducted corresponding 
to daily practice. The study population will consist of 72 
adult patients (age 18–75 years) with severe recurrent 
vesicular hand eczema. Patients are treated with either 
(group I) alitretinoin 30 mg once daily or (group II) 
cyclosporine with a starting dose of 5 mg/kg/day and a 
decrease in dosage after 8 weeks to 3–3.5 mg/kg/day. 
The treatment period is 24 weeks for both drugs. Primary 
endpoint for efficacy is response to treatment, defined 
as an improvement of ≥2 steps on a Physician Global 
Assessment, using a validated Photoguide, after 24 weeks 
of treatment. Secondary endpoints are improvement 
of Hand Eczema Severity Index, Quality of Life in Hand 
Eczema Questionnaire and a Patient Global Assessment. 
Adverse events and time to response will be registered. 
Furthermore, cost-utility, quality-adjusted life years and 
cost-effectiveness will be assessed with the EQ-5D-5L 
questionnaire while monitoring costs.
Ethics and dissemination This protocol was reviewed 
and approved by the Medical Ethical Review Board of the 
University Medical Centre Groningen (reference METc 
2015/375). The study will be conducted according to the 
principles of the Declaration of Helsinki, in accordance 
with the Dutch Medical Research Involving Human 
Subjects Act.
trial registration number NCT03026946; Pre-results.
IntroduCtIon  
Hand eczema is a common condition. It can 
have far-reaching personal, psychological and 
occupational consequences that may have a 
drastic impact on the life of those affected. A 
point prevalence of 4% and a 1-year-period 
prevalence up to 10% in the general popula-
tion in Sweden have been reported.1 A Danish 
study in young adults showed an incidence of 
8.8 per 1000 person-years, a point prevalence 
of 7.1% and a 1-year-period prevalence of 
14.3%. Women are significantly more often 
affected than men.2 
The clinical presentation of severe hand 
eczema varies widely, ranging from chronic 
fissured skin to a vesicular eruption or palmar 
hyperkeratosis. The disease could also be 
approached aetiologically, considering 
exogenous factors causing allergic contact 
dermatitis (eg, nickel, perfumes) and irri-
tant contact dermatitis (eg, water, soap) in 
addition to endogenous factors like atopic 
dermatitis.3
strengths and limitations of this study
 ► This study compares two systemic drugs for severe 
recurrent vesicular hand eczema head-to-head and 
aims to answer both a relevant clinical and econom-
ical question.
 ► A strength of the study is that blinded assessment 
of severity will be performed in order to obtain an 
objective result for efficacy, despite the open-label 
design.
 ► The study is limited by the fact that there will be no 
follow-up after the end of treatment at 24 weeks, 
meaning that this study will not address the long-
term efficacy of both drugs.
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There is general consensus concerning the first-line 
treatment of hand eczema in various guidelines. Emol-
lients and topical corticosteroids are considered to be 
the mainstay of treatment in mild and moderate forms. 
If these fail, secondary options like phototherapy and 
systemic treatment are available. However, to date, an 
evidence-based recommendation regarding the treat-
ment of more severe hand eczema cannot be made. 
Particularly, more head-to-head trials are needed.4
Alitretinoin is the only registered systemic treatment 
option for all clinical types of severe chronic hand 
eczema. It is currently the most investigated drug in 
terms of patient numbers in the second-line treatment of 
severe chronic hand eczema. In well-designed, pharma-
ceutical sponsored trials, 30 mg alitretinoin a day resulted 
in a clear or almost clear response in 48% of the partic-
ipants, compared with 17% in placebo. In the hyperker-
atotic subtype 54% responded, compared with 12% in 
the placebo group. In two non-hyperkeratotic subgroups 
(defined as pompholyx (vesicular) and fingertip in the 
study), only 33% and 44% of participants reached clear-
ance or almost clearance, compared with 12%–30% in 
the placebo group.5 6
In our clinical experience, cyclosporine has beneficial 
effects on hand eczema in daily practice. This concerns 
mainly the vesicular subtype in which a response of 68% 
was estimated in a retrospective drug survival study.7 
Other small studies have also shown that cyclosporine 
may have a beneficial effect on hand eczema. In a case 
study, Reitamo and Granlund reported that 87.5% of the 
patients with a chronic dermatitis on the hands responded 
to cyclosporine treatment within a few weeks.8 In a study 
by Granlund et al, 41 patients were treated with cyclo-
sporine for chronic hand eczema; 50% of the patients 
reported a beneficial effect of the treatment.9 In a second 
open-label study, 27 patients treated for 6 weeks with 
oral cyclosporine 3 mg/kg/day showed a 1-year success 
rate of 74% for chronic hand eczema.10 A previous trial 
comparing alitretinoin with cyclosporine in atopic hand 
eczema ended prematurely due to the inability to include 
the total number of participants.11
In several European countries, cyclosporine is regis-
tered for use in patients with atopic dermatitis. Schmitt 
et al performed a meta-analysis of controlled and uncon-
trolled trials of cyclosporine treatment in patients with 
atopic dermatitis. Fifteen studies including 602 patients 
were analysed. All studies reported a decrease in the 
mean severity of atopic dermatitis with a relative effective-
ness of 55% (95% CI 48% to 62%) after 6 to 8 weeks of 
cyclosporine treatment.12
Although alitretinoin is the only registered systemic 
treatment for severe chronic hand eczema, this treatment 
has never been compared with immunomodulating/
immunosuppressive systemic drugs that are currently 
considered to be a third-line alternative treatment for this 
condition.4 Since alitretinoin showed a good response in 
hyperkeratotic subtypes, the drug should be used as first 
systemic choice in this subtype. In the vesicular subtype, 
however, its action was less convincing. Cyclosporine on 
the other hand showed good response in vesicular hand 
eczema. This trial aims to compare alitretinoin with cyclo-
sporine in the treatment of severe chronic recurrent 
vesicular hand eczema. The study assesses the efficacy of 
both treatments and will show head-to-head results, which 
should contribute to uncovering the best treatment 
strategy for hand eczema.
objECtIvEs
Primary objective: to compare the efficacy of alitretinoin 
and cyclosporine in patients with severe recurrent vesic-
ular hand eczema.
Secondary objectives:
 ► To compare time to response.
 ► To compare health-related quality of life
 ► To compare improvement in severity of hand eczema, 
as assessed by the patient.
 ► To compare safety.
 ► To compare cost-utility and cost-effectiveness.
MEthods And AnAlysIs
study design
This study is designed as a randomised prospective open-
label study. Assessment of disease severity, laboratory 
measurements and quality of life in this study will be 
conducted comparable with daily practice assessments. 
The duration of the study for an individual patient is 24 
weeks. Planned inclusion period is 2 years.
study population
The study population will consist of adult patients with 
severe recurrent vesicular hand eczema. Recurrent vesic-
ular hand eczema will be diagnosed following the criteria 
of the Danish Contact Dermatitis Group.13 The definition 
of recurrent vesicular hand eczema is recurrent eruptions 
of vesicles on the palms and/or on the sides of the fingers 
and possibly also on the palmar aspects of the fingers and 
around the fingernails. Eruptions may occur at intervals 
of weeks or months. The severity of the hand eczema at 
screening will be graded by means of a Physician Global 
Assessment using a validated Photoguide.14 Woman in the 
fertile age will be required to use proper contraception 
methods. Men and women of all ethnicities of 18 years 
and older will be recruited. Patients meeting all inclusion 
criteria, while not meeting any of the exclusion criteria, 
will be asked to participate. See figure 1 for a study flow 
chart.
Inclusion criteria
In order to be eligible to participate in this study, a subject 
must meet all of the following criteria:
 ► Age ≥18 years and ≤75 years.
 ► Severe or very severe recurrent vesicular hand eczema 
for a minimum duration of 3 months as defined by a 
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 ► Refractory to standard therapy, defined as:
 – Patient received treatment with topical cortico-
steroids of class II or higher for at least 8 weeks 
within 3 months before enrolment, with either no 
response or a transient response.
 – Patient has also received standard skin care, includ-
ing emollients and barrier protection as appropri-
ate, without significant improvement.
 – Patient has avoided irritants and contact allergens, 
if identified, without significant improvement.
 ► Women of childbearing potential are required to use 
at least two forms of contraception for at least 1 month 
before starting treatment, during treatment and for at 
least 1 month after finishing treatment; these women 
are required to take monthly pregnancy tests.
 ► Able to provide written informed consent.
 ► Able to speak and read the Dutch language.
Exclusion criteria
A potential subject who meets any of the following criteria 
will be excluded from participation in this study:
General criteria prior to randomisation
 ► Treated with alitretinoin or cyclosporine in the 
previous 3 months.
 ► Other morphological types of hand eczema as defined 
by the Danish Contact Dermatitis Group.13
 ► Patients with predominantly atopic dermatitis, in 
whom the hands are also involved, but no main 
concern. (Patients with controlled atopic dermatitis, 
in which the hands are mainly affected, are eligible 
for inclusion.)
 ► Psoriasis of the hands.
 ► Active bacterial, fungal or viral infection of the hands.
Figure 1 Study flow chart. *Lack of efficacy defined as no improvement assessed by the Physician Global Assessment 
(Photoguide) (at least one step improvement is necessary to continue treatment after 12 weeks).
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 ► Pregnant/lactating or planning to become pregnant 
during the study period.
 ► Treatment with systemic immunosuppressive medica-
tion or UV radiation within the previous 4 weeks.
 ► Mentally incompetent.
 ► Immunocompromised status (to be determined by 
investigator or treating physician).
 ► Uncontrolled arterial hypertension (minimally three 
measurements). Systolic pressure >160 mm Hg or 
diastolic pressure >95 mm Hg, despite starting antihy-
pertensive medication.15
 ► Known or suspected allergy to ingredients in the study 
medications.
 ► Inclusion in a study of an investigational drug within 
60 days prior to start of treatment.
 ► Current malignancy (other than successfully treated 
non-metastatic cutaneous squamous cell or basal cell 
carcinoma and/or localised carcinoma in situ of the 
cervix).
 ► Current active pancreatitis.
 ► Evidence of alcohol abuse or drug addiction.
 ► Malabsorption.
 ► Currently active gout.
 ► Recurring convulsions/epilepsy.
 ► Living vaccine (including BCG, varicella, measles, 
mumps, rubella, yellow fever, oral polio and oral 
typhoid) in the last 2 weeks or the planned applica-
tion of such a vaccine during the study period.
 ► Chronic or recurrent infectious diseases.
 ► Contact sensitisations with clinical relevance to the 
hands, in which exposure to allergens is not avoided.
 ► Hypervitaminosis A due to the use of vitamin A supple-
ments containing >2000 IU.
 ► Use of drugs with potential to change the effective 
dose of study drugs within the previous 2 weeks.
Laboratory exclusion criteria post-randomisation
 ► Alanine aminotransferase (ALAT) and/or aspartate 
aminotransferase (ASAT) values >200% of the upper 
limit of normal.
 ► Impaired renal function as indicated by a clinically 
relevant abnormal creatinine value (to be determined 
by investigator or treating physician).
 ► Anaemia as indicated by a clinically relevant lowered 
haemoglobin value (to be determined by investigator 
or treating physician).
Alitretinoin specific
 ► Triglycerides >200% of the upper limit of normal.
 ► Cholesterol or low-density lipoprotein cholesterol 
values >200% of the upper limit of normal.
 ► Uncontrolled hypothyroidism (to be determined by 
investigator or treating physician).
Cyclosporine specific
 ► Impaired renal function as indicated by a clinically 
relevant abnormal creatinine value (to be determined 
by investigator or treating physician).
 ► Uraemia.
 ► Hyperkalaemia.
 ► Hyperuricaemia in patients with a medical history of 
gout.
Recruitment and consent
Recruitment takes place at a university centre Derma-
tology department, during specialised eczema consulting 
sessions every week. Several Dermatology departments 
in hospitals in the region are provided with the study 
protocol and asked to refer eligible patients. All referred 
hand eczema patients (by general practitioner or derma-
tologist) will visit the department several times for diag-
nostics (patch testing) and initial therapy. Only when 
these patients have a diagnosis of severe or very severe 
recurrent vesicular hand eczema, prove refractory to 
standard therapy, and avoidance of irritants and allergens 
does not give significant improvement (ie, meet the key 
inclusion criteria), they will be approached at the outpa-
tient clinic to participate in the study. Patients will be 
extensively informed about the trial.
It is the responsibility of the investigator, or a person 
designated by the investigator, to obtain written informed 
consent from each individual participating in this study 
after adequate explanation of the aims, methods, objec-
tives and potential hazards of the study. It will also be 
explained to patients that they are completely free to 
refuse to enter the study or to withdraw from it at any 
time for any reason. Patients will be given a period of 
1 week to consider participation before they are asked to 
sign the informed consent form.
treatment of subjects
Interventions
Group I will receive an oral alitretinoin capsule of 30 mg 
once daily for a total of 24 weeks. In a dose-finding study, 
the effectiveness and tolerability of this dose was estab-
lished and it is recommended to use this as the stan-
dard dose for the prescription of alitretinoin in hand 
eczema.5 6 16
Group II will receive oral cyclosporine tablets twice daily 
in a dose of 5 mg/kg/day (split in two doses) and decrease 
this dose after 8 weeks to 3–3.5 mg/kg/day (split in two 
doses).17
Dosage reduction is allowed in both groups in case 
of abnormal findings on physical examination, labora-
tory markers and/or adverse events. For alitretinoin, 
dose can be reduced from 30 mg/day to 10 mg/day, in 
accordance with the Summary of Product Characteristics 
(SPC) text.16 For cyclosporine, in case of increased creat-
inine levels >30% of baseline, laboratory measurement 
should be repeated after 2 weeks. If creatinine levels are 
still increased at least >30%, dosage will be reduced with 
the recommended 30%–50%.15 Developing hypertension 
should be re-evaluated with at least three measurements 
(if necessary by the general practitioner). If repeated 
values of a systolic pressure >160 mm Hg or diastolic pres-
sure >105 mm Hg are found, the general practitioner will 
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be requested to start an antihypertensive drug (preferably 
calcium channel blockers).15 18
Preparation and labelling of the study drugs will be 
carried out according to usual practice by the commu-
nity pharmacy, honouring Good Manufacturing Prac-
tice guidelines. Medication will be dispensed and 
used in the same way as in routine clinical practice, 
according to (among other regulations) their marketing 
authorisations.
Use of concomitant medication
All patients will be given an emollient cream with instruc-
tions to apply it frequently (advice: minimum two times 
a day). One week before the first intake of study drugs, 
concomitant treatment with a topical class II corticoste-
roid (eg, triamcinolone acetonide ointment 0.1%) at 
maximum is permitted when needed, with a maximum 
application of one finger-tip-unit (FTU) for each hand 
daily.19 This also applies for concomitant topical cortico-
steroid therapy during the study period. High-potency 
topical corticosteroids are not allowed as maintenance 
therapy.
Generally prohibited concomitant treatments during 
therapy comprise systemic corticosteroids, other reti-
noids, any other systemic or topical anti-eczema therapy, 
phototherapy, immunosuppressive or cytostatic drugs.
Alitretinoin specific prohibited concomitant treatment: 
vitamin A supplements, tetracyclines and azole antimy-
cotics. St John’s wort should not be taken because of a 
possible interaction with hormonal contraceptive drugs. 
This could possibly result in a pregnancy, which is abso-
lutely contraindicated because of the teratogenic nature 
of alitretinoin.16
Cyclosporine specific prohibited concomitant treat-
ment: medicines that are substrates for the multidrug 
efflux transporter P-glycoprotein or the organic anion 
transporter proteins. This could result in elevated plasma 
concentrations, which are associated with serious and/
or life-threatening events, for example, bosentan, dabiga-
tranetexilate and aliskiren.
Inductors of CYP3A4 and/or P-glycoprotein will prob-
ably lead to a decrease of cyclosporine plasma concentra-
tions. Examples of these are barbiturates, carbamazepine, 
oxcarbazepine, phenytoin, nafcilline, intravenous sulfad-
imine, probucol, orlistat, St John’s wort (Hypericum 
perforatum), ticlopidine, sulfinpyrazon, terbinafine and 
bosentan. Rifampicine induces metabolism of cyclospo-
rine in the intestines and liver. Octreotide decreases oral 
absorption of cyclosporine.
Inhibitors of CYP3A4 and/or P-glycoprotein can 
increase cyclosporine plasma concentrations. Exam-
ples of these are nicardipine, metoclopramide, methyl-
prednisolone (high doses), allopurinol, cholic acid and 
derivatives, protease inhibitors, imatinib, colchicine and 
nefazodon.
Other drugs that increase cyclosporine plasma concen-
tration are macrolide antibiotics, azole antimycotics, 
verapamil, telaprevir, amiodarone, danazol, diltiazem 
and lercanidipine. Furthermore, grapefruit and grape-
fruit juice can have an increasing effect on cyclosporine 
plasma concentration.
Also prohibited are drugs that result in an increased 
risk for nephrotoxicity when combined with cyclospo-
rine, such as aminoglycosides (including gentamycin, 
tobramycin), amphotericin B, ciprofloxacin, vancomycin, 
trimethoprim (+sulfamethoxazole); fibric acid derivatives 
(eg, bezafibrate, fenofibrate); non-steroidal anti-inflam-
matory drugs (including diclofenac, naproxen, sulindac); 
melphalan, histamine H2-receptor antagonists (eg, 
cimetidine, ranitidine), methotrexate.
The dosage of statins needs to be decreased when treat-
ment with cyclosporine is started because of a possible 
increase in plasma concentration of statins.17
Escape medication
In case of an exacerbation or postponed treatment effect, 
patients are allowed to receive a maximum of three 
courses of rescue medication: mometasone furoate oint-
ment once daily for 1 week, with a maximum application 
of one FTU for each hand daily.19
outcome measures
Primary outcome measure
Severity of hand eczema
The PGA, based on a validated Photoguide developed 
by Coenraads et al, covers five degrees of severity (clear, 
almost clear, moderate, severe, very severe) and takes into 
account the intensity of clinical signs and percentage of 
hand surface involved.14 Response to treatment is defined 
as an improvement of ≥2 steps on the PGA. Very severe 
hand eczema is defined as responding to treatment if 
a status of at least ‘moderate’ is achieved. Severe hand 
eczema is defined as responding to treatment if a status 
of at least ‘almost clear’ is achieved.
In this study, the main endpoint is the between-group 
difference in response to treatment between baseline and 
24 weeks of treatment.
Secondary outcome measures
Severity of hand eczema
 ► Between-group difference in response to treatment 
between baseline and 12 weeks of treatment.
 ► Between-group difference in mean change between 
baseline and weeks 4, 8, 12 and 24, assessed by the 
Hand Eczema Severity Index (HECSI) score.20 The 
HECSI is a physician-rated measurement instru-
ment for severity, based on clinical symptoms only. It 
includes erythema, fissures, vesicles, scaling, oedema, 
papules and measurement of the affected area. The 
score ranges from 0 to 360, with a higher score indi-
cating more severe hand eczema.
 ► Between-group difference in time to response (time 
to first PGA improvement of ≥2 steps). This is only 
measured at control visits so possible outcome is 
limited to 4, 8, 12 and 24 weeks. This will be corrected 
using statistical methods (see statistical paragraph).
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Patient-reported outcome measures (PROMs):
Quality of life
 ► Between-group mean change in quality of life between 
baseline and 12 and 24 weeks, assessed by the Quality 
Of Life in Hand Eczema Questionnaire (QOLHEQ). 
The QOLHEQ is a multi-domain disease-specific 
instrument for hand eczema assessing impairments in 
quality of life. The score ranges from 0 to 120, with 
120 indicating worst quality of life.21 22
Patient-reported improvement
 ► Between-group difference in patients reporting 
improvement as ‘clear or almost clear’ compared with 
baseline at weeks 12 and 24, assessed by Patient Global 
Assessment (PaGA). The PaGA takes signs and symp-
toms into account. It covers six degrees of improve-
ment: ‘clear or almost clear’ (at least 90% clearing 
of disease signs and symptoms compared with base-
line), ‘marked improvement’ (at least 75% clearing), 
‘moderate improvement’ (at least 50% clearing), 
‘mild improvement’ (at least 25% clearing), ‘no 
change’ or ‘worsening’.6
Safety and tolerability
 ► Adverse events in both groups will be registered.
Cost-utility and cost-effectiveness
 ► Between-group difference in mean quality-adjusted 
life years (QALYs) will be measured by the EQ-5D-5L 
score at baseline, week 12 and week 24. The EQ-5D-5L 
is a measure for health-related quality of life (HRQoL) 
and utility values. The EQ-5D-5L questionnaire 
includes a descriptive system, which comprises five 
dimensions of health: mobility, self-care, usual activi-
ties, pain/discomfort and anxiety/depression. More-
over, it includes a visual analogue scale (VAS), which 
records the respondent’s self-rated health status on a 
graduated (0–100) scale.23
 ► Direct medical costs will be determined using stand-
ardised prices for consultation, treatment (medica-
tion; alitretinoin or cyclosporine, topical treatment 
with corticosteroids and emollients, if necessary oral 
or topical treatment with antibiotics), diagnostic tests, 
laboratory measurements, visits to the general prac-
titioner for hand eczema and hospital admissions 
(inpatient and/or daycare). Included patients will be 
asked to keep track of how much they spend on over-
the-counter medication and other products for their 
hand eczema (out-of-pocket costs). Direct non-med-
ical costs, consisting of travel costs, will be determined 
using average travel costs to the hospital as deter-
mined by relevant Dutch guidelines on cost-studies in 
healthcare.24 25
 ► Indirect costs, consisting mainly of productivity loss, 
will be also be calculated using tables from the guide-
lines with average income of Dutch workers stratified 
by age and gender, corrected for shift working/irreg-
ular working hours.24
Other study parameters
The following parameters will be registered: age, sex, 
body mass index, current and/or previous atopic derma-
titis (both defined by U.K. Working Party criteria),26 age 
of onset of atopic dermatitis, age of onset of hand eczema, 
work/activities (based on risk professions as named in the 
European Guideline on hand eczema),4 current use of 
statins, current use of thyromimetics, currently smoking 
and amount of pack-years. Pack-years are calculated by 
multiplying the total years smoked with the average packs 
per day smoked over these years.27 For this, the online 
Smoking Pack Years Calculator, created by Dr N J Masters 
and C Tutt, will be used.28
study procedures and overview
Procedures part of standard medical treatment
According to daily practice, a detailed patient history is 
obtained of all newly referred patients with hand eczema 
and they are planned for patch testing to exclude contact 
allergy. During this first period, patients are treated with 
topical corticosteroids and emollients. A structured educa-
tion programme by a nurse on provoking factors and treat-
ment is provided. If a relevant contact allergy is ruled out 
and the hand eczema proves to be refractory to topical 
therapy and/or UV therapy, the next step is systemic therapy. 
These patients are a candidate for the current study if they 
are diagnosed with severe or very severe recurrent vesicular 
hand eczema.
Laboratory analysis is performed to verify contraindi-
cations for alitretinoin or cyclosporine. During therapy, 
standard monitoring of blood values is carried out, 
according to SPC texts and current guidelines. At every 
visit, the PGA for severity is determined and the hand 
eczema is scored using the HECSI, corresponding to daily 
practice. Furthermore, HRQoL is scored with a Dutch 
version of the QOLHEQ at the start of therapy, at week 
12 and week 24.
Standard laboratory tests to be performed include:
Alitretinoin: at weeks 0, 4, 8, 12 and 24, laboratory tests 
are carried out, including full blood count, ASAT, ALAT, 
alkaline phosphatase (ALP), gamma-glutamyltransferase 
(γ-GT), serum creatinine, cholesterol, triglycerides, 
high-density lipoprotein, thyroid-stimulating hormone 
(TSH), T4 and glucose. Also, a urine pregnancy test will 
be carried out.
Cyclosporine: at weeks 0, 4 and 12, laboratory tests are 
carried out, including full blood count, potassium, magne-
sium, ASAT, ALAT, ALP, γ-GT, bilirubin, LDH, albumin, 
serum creatinine, uric acid, cholesterol and triglycerides.
At weeks 4 and 12, cyclosporine trough levels will be 
determined.
At weeks 8 and 24, serum creatinine will be determined.
Procedures extra for this study
Patients will be given 1 week to consider participation. 
Due to this, a maximum of one extra visit is needed to 
randomise the patient and obtain baseline data. The 
PaGA one-item questionnaire will be obtained at weeks 12 
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and 24. This procedure is only extra in terms of obtaining 
a quantitative assessment of the qualitative report that a 
patient provides in daily practice.
Patients will be asked to keep track of out-of-pocket 
costs on products for their hand eczema. During each 
visit, patients will be asked for direct and indirect medical 
and non-medical costs. Furthermore, the EQ-5D-5L ques-
tionnaire is obtained at weeks 0, 12 and 24, which is extra 
compared with daily practice.
Serum Thymus and Activation-Regulated Chemokine 
(TARC/CCL17) will be determined at all visits to study 
whether this chemokine is a suitable biomarker for hand 
eczema severity and/or disease activity over time.
No diagnostic procedures or other treatments will be 
postponed for patients participating in this study.
In table 1, a systematic overview of the study is presented.
safety
Alitretinoin
Main risks in the alitretinoin group are16:
 ► Teratogenicity of the study drugs.
 ► Occurrence of allergic/anaphylactic reactions.
 ► Depression with anxiety, mood changes and suicidal 
tendencies.
 ► Sunburn.
 ► Xerostomia, xerosis cutis.
 ► Keratoconjunctivitis sicca, keratitis, blurred (night) 
vision, cataract. Care must be taken when driving a 
vehicle or when operating machines.
 ► Myalgia, arthralgia, increase of creatine kinase (CK)
values.
 ► Exostosis, ankylosing spondylitis.
 ► Headache.





Baseline V1 V2 V3 V4
Week −1 0 4 8 12 24
Screening/baseline
Check for clinical eligibility (inclusion/exclusion) x





Laboratory exclusion criteria post-randomisation x
Start medication x
Treatment
Escape medication assessment x x x x




x x x x x
Quality of life questionnaire
QOLHEQ
x x x
PaGA of improvement x x
Costs





Laboratory control x x x x x
Concomitant medication x x x x x
Adverse events x x x x
Blood pressure measurement (cyclosporine only) x x x x x
If applicable: premature withdrawal assessment x x x x x
Patients are permitted to deviate from the schedule with a maximum of 7 days during weeks 0–8. From week 9, a maximum deviation of 14 
days is permitted.








pen: first published as 10.1136/bmjopen-2017-020192 on 11 July 2018. Downloaded from 
8 Oosterhaven JAF, Schuttelaar MLA. BMJ Open 2018;8:e020192. doi:10.1136/bmjopen-2017-020192
Open access 
 ► Blushing.
 ► Increase of cholesterol and triglycerides, with ulti-
mately pancreatitis.
 ► Decrease of TSH and T4.
 ► Increased liver transaminases.
 ► Decrease in effective dose of simvastatin.
 ► Change at scarring or dermatitis during therapy and 





 ► Benign intracranial hypertension (rare and most seen 
in combination with tetracyclines).
 ► Inflammatory bowel disease (rare).
 ► Vasculitis (rare).
Alitretinoin is a derivative of vitamin A. Alitretinoin 
has been administered in oncological clinical studies at 
dosages of more than 10 times the therapeutic dosage 
given for chronic hand eczema. The adverse effects 
observed were consistent with retinoid toxicity and 
included severe headache, diarrhoea, facial flushing 
and hypertriglyceridaemia. These effects were reversible.
It can be concluded that the (reversible) effects can be 
properly managed.
Cyclosporine
Main risks in the cyclosporine group are17:
 ► Renal toxicity.
 ► Hepatotoxicity.
 ► Hypertension, flushing.
 ► Nausea/vomiting, abdominal discomfort.
 ► Headache.
 ► Diarrhoea.
 ► Anaemia, thrombocytopenia.
 ► Leucopenia.
 ► Hyperlipidaemia.
 ► Hyperkalaemia, hypomagnesaemia, hyperuricaemia, 
hyperglycaemia.




 ► Muscle cramps.
 ► Tiredness.
 ► Gynaecomastia.
 ► Occurrence of allergic/anaphylactic reactions.
 ► Pre-existing infections may also be aggravated and 
reactivation of polyomavirus infections may lead to 
polyomavirus-associated nephropathy or to John 
Cunningham (JC) virus-associated progressive multi-
focal leukopathy. Serious and/or fatal outcomes have 
been reported.
 ► Increased risk of lymphomas and other malignancies 
(mainly when combining multiple immunosuppres-
sive drugs).
 ► Increased risk of infections.
 ► Decreased effect of live vaccinations.
Experience with acute overdosage of cyclosporine is 
limited. Oral doses of cyclosporine of up to 10 g (about 
150 mg/kg) have been tolerated with relatively minor 
clinical consequences, such as vomiting, drowsiness, 
headache, tachycardia and in a few patients moder-
ately severe, reversible impairment of renal function. 
However, serious symptoms of intoxication have been 
reported following accidental parenteral overdosage 
with cyclosporine in premature neonates.
In all cases of overdosage, general supportive measures 
should be followed and symptomatic treatment applied. 
Forced emesis and gastric lavage may be of value within 
the first few hours after oral intake. Cyclosporine is not 
dialysable to any great extent, nor is it well cleared by 
charcoal haemoperfusion.
It can be concluded that the (reversible) effects can be 
properly managed.
Withdrawal of individual subjects
Subjects can leave the study at any time for any reason 
if they wish to do so, without any consequences. The 
investigator can decide to withdraw a subject from the 
study, or to stop treatment, for medical reasons. Specific 
criteria for withdrawal are:
 ► Evidence of pregnancy.
 ► Occurrence of serious adverse events.
 ► Lack of efficacy at 12 weeks, defined as no improve-
ment assessed by the PGA (at least one step improve-
ment is necessary to continue treatment after 12 
weeks).
 ► Use of prohibited concomitant therapy, or a need for 
their use.
 ► The need for more than three courses of rescue 
medication.
 ► Anaphylactic reaction or other severe systemic reac-
tion to study drug intake.
 ► Diagnosis of malignancy during study, excluding 
non-metastatic cutaneous squamous cell or basal cell 
carcinoma and/or localised carcinoma in situ of the 
cervix.
 ► Any infection that is opportunistic and other infec-
tions whose nature or course may suggest an immuno-
compromised status.
 ► Administration of a living vaccine.
 ► Developing hypertension (minimally three measure-
ments). Systolic pressure >160 mm Hg or diastolic 
pressure >95 mm Hg, despite starting antihyperten-
sive medication.15
 ► Severe laboratory abnormalities including:
 – ALAT and/or ASAT values >300% of the upper 
limit of normal.
 – Triglycerides >9 mmol/L.
 – Creatinine increase of >30%, despite dose 
reduction.
 ► Intercurrent severe illness or major surgery.
 ► Protocol violations or if the requirements of the 
protocol are not respected.
 ► Patient lost to follow-up.
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Serious adverse events and suspected unexpected serious adverse 
reactions
A serious adverse event (SAE) is any untoward medical 
occurrence or effect at any dose that:
 ► Results in death.
 ► Is life threatening (at the time of the event).
 ► Requires hospitalisation or prolongation of existing 
inpatients’ hospitalisation.
 ► Results in persistent or significant disability or 
incapacity.
 ► Is a congenital anomaly or birth defect.
Any other important medical event that may not 
result in death, be life threatening or require hospital-
isation may be considered a serious adverse experience 
when, based on appropriate medical judgement, the 
event may jeopardise the subject or may require an inter-
vention to prevent one of the outcomes listed above.
Unexpected adverse reactions are suspected unex-
pected serious adverse reactions if the following three 
conditions are met:
1. The event must be serious (see SAE).
2. There must be a certain degree of probability that the 
event is a harmful and an undesirable reaction to the 
medicinal product under investigation, regardless of 
the administered dose.
3. The adverse reaction must be unexpected, that is to 
say, the nature and severity of the adverse reaction are 
not in agreement with the product information as re-
corded in the SPC texts.
randomisation, blinding and treatment allocation
Randomisation is carried out by a computer program 
(ALEA, http://www. aleaclinical. eu). Patients will be 
randomly assigned in a 1:1 ratio to the two treatment 
arms. We will use block randomisation with a random 
block size of 4 or 6 (random generated blocks). No strati-
fication will be done. This is a study with blinded efficacy 
assessors, who are unaware of treatment allocation. The 
participants and treating physician will be aware of treat-
ment allocation. Efficacy assessment will be carried out by 
one main blinded assessor and a second assessor in case 
the first assessor is unable to be present. These assessors 
are trained by the primary investigator and are experi-
enced in assessing hand eczema by PGA and HECSI in 
daily practice. The first assessor is expected to perform 
around 95% of all assessments. Blinding will be broken 
after analysing the data.
statistical analyses
Hypothesis and sample size calculation
This trial is designed to demonstrate a superior response 
to cyclosporine compared with alitretinoin in the 
treatment of severe recurrent vesicular hand eczema. 
Response to treatment is defined as an improvement 
of ≥2 steps on the PGA, based on a validated Photoguide 
developed by Coenraads et al14 at 24 weeks of treat-
ment. A sample size of 31 in each group will have 80% 
power to be able to reject the null hypothesis of no 
difference between alitretinoin and cyclosporine, using 
a χ2 test with a two-sided 0.05 significance level. In this 
calculation, we use the following assumptions: rando-
misation ratio is 1:1, and we expect the percentage of 
responders in the alitretinoin group to be 33%.6 From 
a retrospective study and other case studies, we esti-
mate 68% responders in the cyclosporine group.7 We 
anticipate a drop-out of maximally 15% of randomised 
patients; a small percentage prior to first application of 
study drugs due to excluding laboratory measurements 
and a larger percentage during follow-up, mainly due 
to subjective side effects. We therefore plan to include 
72 patients in total, 36 in the alitretinoin group and 36 
in the cyclosporine group.
This was calculated with the sample size calculator 
of the Department of Statistics, University of British 
Columbia, Canada, available online (http://www. stat. 
ubc. ca/~ rollin/ stats/ ssize/ b2. html).
For all analyses, we will use Bonferroni adjustment if 
necessary.
Primary analysis
Severity of hand eczema
Between-group difference in response to treatment 
between baseline and 24 weeks of treatment. For compar-
ison of proportions in the alitretinoin and cyclosporine 
group, a χ2 test, or Fisher’s exact test if appropriate, will 
be used. Presenting the data as ORs derived from logistic 
regression analysis will be considered as an alternative 
reporting method.
Secondary analyses
Severity of hand eczema
 ► Between-group difference in response to treatment 
between baseline and 12 weeks of treatment. For 
comparison of proportions in the alitretinoin and 
cyclosporine group, a χ2 test will be used.
 ► Between-group difference in mean change between 
baseline and weeks 4, 8, 12 and 24, assessed by the 
HECSI score. This will be reported graphically. For 
comparison of mean change between the alitretinoin 
and cyclosporine group at weeks 12 and 24, Student’s 
t-test or Mann-Whitney U test will be used, depending 
on distribution of data.
 ► Between-group difference in time to response (time 
to first PGA improvement of ≥2 steps compared with 
baseline). Because this outcome measure is inter-
val-censored, the cumulative incidence of ‘response’ 
will be analysed using actuarial life table analysis and 
weighted log-rank tests for interval censored data; in 
particular the group proportional hazards model29 
and a generalised Wilcoxon-Mann-Whitney test,30 
which emphasises early events. The exact permutation 
value for the scores of the group proportional hazards 
model will be calculated, along with Wilcoxon-Mann-
Whitney tests and the non-parametric maximum-like-
lihood estimate of the survival distribution function.31
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Patient-reported outcome measures (PROMs):
Quality of life
 ► Between-group mean change in quality of life 
between baseline and 12 and 24 weeks, assessed by the 
QOLHEQ. Clinically relevant improvement is defined 
as an absolute improvement of 15 points (theoreti-
cally corresponding to an improvement of ≥1 point on 
50% of the questions) compared with baseline. For 
comparison of proportions of patients rated as having 
clinically relevant improvement in the alitretinoin 
and cyclosporine group, a χ2 test will be used.
Patient-reported improvement
 ► Between-group difference in patients reporting 
improvement as ‘clear or almost clear’ at weeks 12 
and 24, assessed by PaGA. For comparison of propor-
tions of patients rated as ‘clear or almost clear’ in the 
alitretinoin and cyclosporine group, a χ2 test will be 
used.
Safety and tolerability
 ► Descriptive statistics will be used to present adverse 
events.
Cost-utility and cost-effectiveness
 ► For both groups (alitretinoin and cyclosporine), the 
mean EQ-5D scores overall and of each dimension 
will be reported. Results from the descriptive system 
of the EQ-5D-5L will be converted to a utility index 
value, a population-based (social) value specific for 
the Netherlands. With this value, Dutch utility values 
will be calculated in order to determine the QALYs 
over the study period. Mean values of the EQ-VAS will 
be reported with a 95% CI. For comparison of means, 
Student’s t-test or Mann-Whitney U test will be used, 
depending on distribution of data.
 ► The incremental cost-effectiveness ratio will be calcu-
lated and reported as €/QALY.
 ► A regression model will be used to estimate the associ-
ation between QALYs and the PGA.
Handling of missing data
All analyses will be based on the intention-to-treat prin-
ciple to guard against attrition bias. Subjects might want 
to withdraw because the study drug works insufficient and 
they might also want to withdraw when their hand eczema 
is cured.
Missing values will be handled in a way that is depen-
dent on assumptions about the missing data. If the extent 
and pattern of missing data is known (eg, missing at 
random, missing completely at random, missing not at 
random), an analysis will be chosen that is valid under 
a plausible assumption about the missing data (probably 
mixed models). This is according to a strategy proposed 
by White et al.32
data handling
Data will be handled confidentially. Data derived from 
the questionnaires and other paper source documents 
will be coded using sequential administration numbers. A 
subject identification code list is used to link the data to 
the subjects. The code is not based on the patient initials 
and birth date. The code will be safeguarded by the prin-
cipal investigator (MLAS). The documents will be stored 
in a locked room. The digital source data will be saved in 
subsections of the subject’s medical file. These data will 
be accessible to the principal investigator and the investi-
gator, and also to other treating physicians. Data will not 
be accessed by the blinded efficacy assessors. All data will 
be recorded in electronic case report forms (eCRFs) in 
Utopia (software for electronic data capture) developed 
by the Trial Coordination Centre, linked to the University 
Medical Centre Groningen. The eCRFs will only be acces-
sible with the username and password of the responsible 
investigator.
Data will be saved for 15 years after completion of this 
study.
All the data will be saved in accordance with the Dutch 
Personal Data Protection Act.
Monitoring
A certified monitor will carry out monitoring of this study. 
The monitor will get read-only access to the digital and 
paper documents of participants. The goal of this moni-
toring is to review if
 ► The rights and well-being of subjects are being 
protected.
 ► The reported data are right and fully reproducible.
 ► The execution of the study is in accordance with this 
protocol and relevant legal requirements.
Data safety monitoring board
No data safety monitoring board (DSMB) is established 
since this study will be conducted corresponding to daily 
practice. In case of life-threatening diseases, usually the 
implementation of a DSMB is indicated from an ethical 
point of view. However, hand eczema is a non-critical indi-
cation. Frequent laboratory assessments will reduce the 
possibility of SAEs to a minimum. The patient population 
in this clinical trial exists of legal competent adults and 
the study drugs alitretinoin and cyclosporine are well-in-
vestigated, well-characterised drugs.
Patient and public involvement
In the Netherlands, there is no patient association exclu-
sively for patients with hand eczema. However, multiple 
patients with hand eczema are members of the associa-
tion of atopic dermatitis patients (‘De Vereniging voor 
Mensen met Constitutioneel Eczeem’, www. vmce. nl). 
This association has 1500 members and a website with 
up to 2000 hits a day. One committee member and two 
patients from this organisation contributed to our study 
design by participating in a focus session concerning all 
aspects of our study, but in particular PROMs, logistics 
from a patient perspective and patient-friendliness of the 
study. These patients also participated in composing and 
refining the patient information material. Before and 
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after the study, the website and newsletter of the patient 
association is used to announce start (drawing attention 
to the study) and end (announce results) of the study.
EthICs And dIssEMInAtIon
Ethics
The study will be conducted according to the princi-
ples of the Declaration of Helsinki (seventh revision, 
Fortaleza, Brazil, October 2013), in accordance with the 
Medical Research Involving Human Subjects Act (WMO) 
and also in accordance with the International Confer-
ence on Harmonisation Good Clinical Practice Guide-
lines (ICH-GCP).
In this trial, both groups are treated with a drug, known 
to be beneficial to hand eczema in a considerable amount 
of patients. So the intended benefit of both study drugs is 
to reduce the severity of hand eczema.
We hypothesise that cyclosporine has a superior efficacy 
compared with alitretinoin in severe chronic recurrent 
vesicular hand eczema. If this hypothesis is confirmed, 
there could be a practical as well as a financial implica-
tion. Practically, more responding patients to cyclospo-
rine lead to a greater beneficial effect on hand eczema 
in this patient group. Financially, cyclosporine is a lot 
less expensive than alitretinoin. If cyclosporine shows 
superior efficacy in severe recurrent hand eczema, this 
could lead to an official registration. This, in turn, could 
mean a decrease in financial burden for the treatment of 
patients with severe recurrent vesicular hand eczema in 
the population.
We deem the overall risks for patients participating in 
this study to be acceptable because of the tight inclusion 
and exclusion criteria (ensuring a relatively healthy study 
population), combined with regular laboratory assess-
ments to enhance safety monitoring. Furthermore, prior 
experience with both study drugs in daily practice has 
improved our capability to manage risks. The remaining 
risk is therefore small and does not differ from regular 
daily practice.
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